Key points are not available for this paper at this time.
ER-low/HER2-negative tumours had a high rate of pCR after the KEYNOTE-522 regimen. Our results suggest that patients with ER-low HER2-negative BC should be treated as ER-null/HER2-negative BC in the neoadjuvant setting to maximise pCR.
Cherifi et al. (Tue,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: